The Specials Movie Stills
The Specials Movie Stills
The Specials Movie Stills
LONDON, March 28, 2023-- FundsDate
It comes after reports suggested Afghan refugees are set to be forced out of hotels as part of new Government plans.
- Investigational New Drug (IND) application submitted for lead candidate SNS-101, a conditionally active VISTA-blocking antibody - - New collaborations with Regeneron, the National Cancer Institute and Washington University in St. Louis will support development of SNS-101 - - Company anticipates advancing a second TMAb™ program to IND-enabling studiesfollowing successful candidate selection - - Strong balance sheet with cash runway into the second half of 2025 - BOSTON, March 28, 2023 (GLOBE NE
Calgary, Alberta--(Newsfile Corp. - March 28, 2023) - Athabasca Minerals Inc. (TSXV: AMI) ("Athabasca" or the "Corporation"), one of North America's largest suppliers of premium sand today announced that its board of directors (the "Board"), together with the support of management, has initiated a process to evaluate potential strategic alternatives intended to maximize shareholder value. As part of the process, the Board will consider a full range of strategic alternatives, which may include fi
Pathway Health Corp. (TSXV: PHC) ("Pathway" or the "Company") is pleased to announce that, further to its press releases of February 3, 2023, February 9, 2023 and February 17, 2023, it has made its third and final draw in the amount of $250,000 (the "Draw Down") under the $1.25 million secured convertible promissory grid note (the "Note") with HEAL Global Holdings Corp. (the "Lender"), an entity controlled by the Company's largest indirect beneficial shareholder Avonlea-Drewry Holdings Inc., and
SÃO PAULO, Brazil, March 28, 2023 (GLOBE NEWSWIRE) -- Semantix Inc., a leading Latin American end-to-end data and enterprise AI platform provider (“Semantix”), today announced the acquisition of ATSaúde’s assets, businesses, and operations as part of the company’s strategic plan to expand its offerings and presence in the Healthcare & Life Science industry in Brazil, with a specific focus on the pharmaceutical industry. Semantix's CEO, Leonardo Santos, said, "The pharma industry offers a huge op
Lemonade shares are down a heart-stopping 93% since their all-time high more than two years ago. The hype around Lemonade wasn't surprising, given the company's use of artificial intelligence to provide a better experience for its current and prospective policyholders. The goal for Lemonade was to make the entire process as user-friendly as possible.
An upgraded partner program allows technology partners enhanced, secure access to Verifone’s Commander Site Controller ecosystem Verifone Announces Horizon Program for its Petroleum and Convenience Store Partners An upgraded partner program allows technology partners enhanced, secure access to Verifone’s Commander Site Controller ecosystem CORAL SPRINGS, Fla., March 28, 2023 (GLOBE NEWSWIRE) -- Verifone, a global FinTech leader and payment solution provider to the world’s best-known brands, toda
Proprietary SaaS Revenue increases 67% in 4Q22 compared to 4Q21SÃO PAULO, Brazil, March 28, 2023 (GLOBE NEWSWIRE) -- Semantix, Inc. (NASDAQ: STIX), a leading Latin American end-to-end data and AI platform provider, today announced its financial results for the fourth quarter and the year ended December 31, 2022. “We believe our positioning at the forefront of emerging data, analytics and AI technologies was reflected in strong Proprietary SaaS revenue growth in the fourth quarter, thus solidifyi
VersaBank ("VersaBank" or the "Bank") (TSX: VBNK) (NASDAQ: VBNK), a leader in digital banking and cybersecurity solutions, today announced that David Taylor, President and Chief Executive Officer, will present virtually at the Investor Summit Conference on on Wednesday, March 29 – 10:30 am ET.
Marks the first time a Phase 2 trial has studied a cannabinol (CBN) formulation as a treatment option for any diseaseData expected to be released in early calendar Q3 2023Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced it has concluded enrollment of its Phase 2 clinical trial ...
Franklin Templeton Canada today announced that it is streamlining its product lineup by adding ETF series to select mutual funds, instead of offering separate standalone ETFs. To facilitate this, nine fund mergers are being proposed, which will be voted on at special meetings of investors to be held on June 29, 2023, in Toronto.
Annual and Special Meeting of Shareholders on April 6, 2023 Release of First Quarter 2023 Results on April 26, 2023 TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- FirstService Corporation (TSX and NASDAQ: FSV) (“FirstService”) announced today that it will hold its Annual and Special Meeting of Shareholders on Thursday, April 6, 2023 at 11:00 a.m. ET. The meeting will be webcast live and can be either accessed via FirstService’s website at www.firstservice.com in the “Investors” section under the “N
Grown Rogue International Inc. ("Grown Rogue" or the "Company") (CSE: GRIN) (OTC: GRUSF), a craft cannabis company operating in Oregon and Michigan, is pleased to report its fiscal first quarter 2023 results for the three months ended January 31, 2023. All financial information is provided in U.S. dollars unless otherwise indicated.
Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone paymentTARRYTOWN, N.Y., and SOUTH SAN FRANCISCO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma Biotherapeutics, Inc. today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development
Revenue grew 17% year over year Recurring revenue grew to 57% of total revenue, an increase of 9% over 2021 Awarded transformative U.S. government contracts and commercial software subscriptions DENVER, March 28, 2023 (GLOBE NEWSWIRE) -- Intermap Technologies (TSX: IMP; OTCQX: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today announced financial results for 2022. For the year ending December 31, 2022, the Company reported revenue of
LOUISVILLE, Ky., March 28, 2023 (GLOBE NEWSWIRE) -- Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX, CREXW), a leading provider of digital signage and media solutions, announced two material updates for shareholders ahead of its anticipated earnings call scheduled for Thursday, March 30, 2023 at 9:00am EST. 1. Status Of Special Committee’s Consideration of Offer from Pegasus Capital Advisors, L.P. As previously reported, on February 2, 2023, the Company rec
SÃO PAULO, Brazil, March 28, 2023 (GLOBE NEWSWIRE) -- Semantix, Inc. (NASDAQ: STIX), a leading Latin American end-to-end data and enterprise AI platform provider (“Semantix”), today announced the launch of Semantix GenAI, an industry-agnostic set of tools designed to streamline the development, training, and deployment of AI applications for businesses. Semantix GenAI empowers businesses to easily and effectively harness the power of AI, optimizing processes through automated decision-making and
This new partnership is a significant growth opportunity, providing MCI patients access to hundreds of ongoing clinical studies and leveraging MCI’s advanced technologies to accelerate research enrolmentTORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- MCI Onehealth Technologies Inc. (“MCI”) (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, and LMC Healthcare, and LMC Clinical Research Inc. dba Centricity Research, Canada’s largest pr
There are many premier marijuana dispensaries across the Kansas City metro, each with its own flare. Vote now to choose your favorite one.